Devonian Health Group Inc. (DVHGF)
USD 0.14
(8.49%)
USD 0.14
(8.49%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -4.28 Million CAD | -44.1% |
| 2022 | -2.87 Million CAD | -27.11% |
| 2021 | -2.26 Million CAD | 50.9% |
| 2020 | -4.6 Million CAD | -22.83% |
| 2019 | -3.74 Million CAD | -17.27% |
| 2018 | -3.19 Million CAD | -27.05% |
| 2017 | -2.51 Million CAD | -9.89% |
| 2016 | -2.28 Million CAD | -2471.15% |
| 2015 | -89.01 Thousand CAD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -601.55 Thousand CAD | 19.36% |
| 2024 Q2 | -1.14 Million CAD | -89.98% |
| 2024 Q3 | -284.72 Thousand CAD | 77.69% |
| 2023 Q3 | -1.43 Million CAD | -45.06% |
| 2023 Q4 | -746 Thousand CAD | 48.1% |
| 2023 FY | -4.13 Million CAD | -44.1% |
| 2023 Q1 | -1.07 Million CAD | -75.69% |
| 2023 Q2 | -990.99 Thousand CAD | 8.0% |
| 2022 Q4 | -613.13 Thousand CAD | 11.81% |
| 2022 Q3 | -695.21 Thousand CAD | 39.67% |
| 2022 FY | -2.87 Million CAD | -27.11% |
| 2022 Q2 | -1.15 Million CAD | -77.0% |
| 2022 Q1 | -650.98 Thousand CAD | -49.42% |
| 2021 Q1 | -810.31 Thousand CAD | 43.7% |
| 2021 Q2 | -886.58 Thousand CAD | -9.41% |
| 2021 Q3 | -806.87 Thousand CAD | 8.99% |
| 2021 FY | -2.26 Million CAD | 50.9% |
| 2021 Q4 | -435.68 Thousand CAD | 46.0% |
| 2020 Q4 | -1.43 Million CAD | -53.36% |
| 2020 FY | -4.6 Million CAD | -22.83% |
| 2020 Q3 | -938.51 Thousand CAD | 14.64% |
| 2020 Q2 | -1.09 Million CAD | -27.29% |
| 2020 Q1 | -863.75 Thousand CAD | 20.12% |
| 2019 Q3 | -1.04 Million CAD | -434.92% |
| 2019 Q4 | -1.08 Million CAD | -3.04% |
| 2019 FY | -3.74 Million CAD | -17.27% |
| 2019 Q1 | -502.79 Thousand CAD | 58.51% |
| 2019 Q2 | -196.18 Thousand CAD | 60.98% |
| 2018 Q3 | -466.87 Thousand CAD | 32.85% |
| 2018 Q4 | -1.21 Million CAD | -159.56% |
| 2018 FY | -3.19 Million CAD | -27.05% |
| 2018 Q1 | -555.31 Thousand CAD | 32.43% |
| 2018 Q2 | -695.27 Thousand CAD | -25.21% |
| 2017 Q3 | -604.8 Thousand CAD | -1702.81% |
| 2017 FY | -2.51 Million CAD | -9.89% |
| 2017 Q2 | -33.54 Thousand CAD | -1026.53% |
| 2017 Q1 | -2978.00 CAD | 54.54% |
| 2017 Q4 | -821.77 Thousand CAD | -35.87% |
| 2016 Q4 | -6551.00 CAD | 82.3% |
| 2016 Q2 | -68.76 Thousand CAD | -21.97% |
| 2016 FY | -2.28 Million CAD | -2471.15% |
| 2016 Q1 | -56.38 Thousand CAD | -100.39% |
| 2016 Q3 | -37.02 Thousand CAD | 46.17% |
| 2015 Q2 | -13.37 Thousand CAD | 67.51% |
| 2015 Q4 | -28.13 Thousand CAD | -344.26% |
| 2015 FY | -89.01 Thousand CAD | 0.0% |
| 2015 Q1 | -41.16 Thousand CAD | 0.0% |
| 2015 Q3 | -6333.00 CAD | 52.65% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Capstone Therapeutics Corp. | -1.25 Million USD | -241.037% |
| Skye Bioscience, Inc. | -13.67 Million USD | 68.67% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 105.233% |
| Nascent Biotech, Inc. | -2.22 Million USD | -92.092% |
| Qrons Inc. | -643.67 Thousand USD | -565.462% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -930.961% |
| Adynxx, Inc. | - USD | Infinity% |
| Arch Therapeutics, Inc. | -5.04 Million USD | 15.087% |
| BioStem Technologies, Inc. | -7.77 Million USD | 44.936% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -523.543% |
| CSL Limited | 3.7 Billion USD | 100.116% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 92.283% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 75.999% |
| Rebus Holdings, Inc. | -664 Thousand USD | -545.094% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -220.752% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -999.527% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 73.009% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 94.033% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 187.153% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -1536.607% |
| SQZ Biotechnologies Company | -75.82 Million USD | 94.351% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | -50.269% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -178.86% |
| Mesoblast Limited | -84.14 Million USD | 94.91% |
| Marizyme, Inc. | -34.08 Million USD | 87.434% |
| Genus plc | 6.4 Million USD | 166.929% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 143.967% |
| Pharming Group N.V. | -4.87 Million USD | 12.217% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | -115.629% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -359.901% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 48.701% |
| ContraFect Corporation | -56.88 Million USD | 92.471% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | 5.956% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -205.525% |
| IMV Inc. | -38.67 Million USD | 88.924% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | -55.713% |
| MultiCell Technologies, Inc. | -722.81 USD | -592507.601% |
| ONE Bio Corp. | 13.68 Million USD | 131.308% |
| Accustem Sciences Inc. | -3.74 Million USD | -14.334% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 92.739% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | -786.724% |
| Q BioMed Inc. | -3.44 Million USD | -24.315% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 221.001% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | -63.022% |
| Biomind Labs Inc. | -1 Million USD | -324.268% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 92.208% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | -47.641% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | 35.568% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | -129.752% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -14200.972% |
| Curative Biotechnology, Inc. | -1.93 Million USD | -121.639% |
| GB Sciences, Inc. | -1.42 Million USD | -201.542% |
| Alpha Cognition Inc. | -9.7 Million USD | 55.866% |
| HST Global, Inc. | -140.9 Thousand USD | -2939.897% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -280.781% |
| Halberd Corporation | -75.05 Thousand USD | -5607.431% |
| Enzolytics Inc. | -2.14 Million USD | -99.34% |
| Agentix Corp. | -1.37 Million USD | -212.259% |
| Resverlogix Corp. | -12.74 Million USD | 66.402% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | -35.197% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -425.04 Million USD | 98.992% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -310.29% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | -46.721% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | -171.214% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | -25.799% |
| AVAX Technologies, Inc. | 6.69 Million USD | 164.0% |
| Zenith Capital Corp. | -8.94 Million USD | 52.103% |
| Genscript Biotech Corporation | -415.79 Million USD | 98.97% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -24487.722% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | -74.455% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -2397.486% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -113.663% |
| Kadimastem Ltd | -3.04 Million USD | -40.891% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -335.284% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -2260.21% |
| LadRx Corporation | -3.82 Million USD | -12.025% |
| Cell Source, Inc. | -4.32 Million USD | 0.969% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -523.543% |
| NovAccess Global Inc. | -2.46 Million USD | -73.646% |
| Affymax, Inc. | -15.04 Million USD | 71.531% |
| Itoco Inc. | -919.14 Thousand USD | -366.026% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | -1.062% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -282.791% |
| Mobile Lads Corp. | -554.55 Thousand USD | -672.415% |
| CytoDyn Inc. | -18.05 Million USD | 76.28% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -16917.986% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -1846.322% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -658.501% |
| SYBLEU INC | -149.18 Thousand USD | -2771.315% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | -135.83% |
| International Stem Cell Corporation | -663 Thousand USD | -546.067% |
| Bioxytran, Inc. | -3.82 Million USD | -12.127% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -8037.209% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -20959.13% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 88.189% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | -164.736% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -482.118% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | -37.686% |
| Neutra Corp. | -229.48 Thousand USD | -1766.531% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 75.578% |
| PureTech Health plc | -146.19 Million USD | 97.07% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 80.069% |
| IXICO plc | -1.43 Million USD | -198.081% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 54.869% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 96.483% |
| CSL Limited | 3.81 Billion USD | 100.112% |
| Cellectis S.A. | -108.85 Million USD | 96.065% |